Rydex Biotechnology Fund Class H (RYOAX)

84.83
Net Asset Value
+1.78%
1 Day
+8.22%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.61%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks to provide capital appreciation. Under normal circumstances- the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives- which primarily consist of futures contracts and options on securities- futures contracts- and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.

Performance

1 month+6.01% 3 years-0.63%
3 months+2.80% 5 years+15.67%
1 year+18.25% Since inception+11.55%
Data through --

Peer Comparisonvs. Health

 RYOAXCategory
Performance 5-yr return+15.67%+14.29%
Expense ratio1.61%1.29%
Risk 5 year sharpe ratio0.600.90
Net assets$286.2M$3.0B
Average market cap$12.7B$9.5B
Average P/E28.821.7
Portfolio turnover207%207%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyRydex Funds
Fund manager & tenureMichael Byrum / 20 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock99.64%
Cash1.51%
International stock0.00%
Fixed income0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ABBV AbbVie6.31%
AMGN Amgen6.10%
GILD Gilead Sciences4.75%
BIIB Biogen4.42%
CELG Celgene3.92%
ILMN Illumina Inc3.65%
VRTX Vertex Pharmaceuticals Inc3.23%
REGN Regeneron Pharmaceuticals2.95%
ALXN Alexion Pharmaceuticals Inc2.70%
BMRN Biomarin Pharmaceutical Inc2.29%